Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. (CHART-1)
This study is currently recruiting participants.
Verified March 2013 by Cardio3 BioSciences
Information provided by (Responsible Party):
First received: December 21, 2012
Last updated: March 21, 2013
Last verified: March 2013
Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure.
Biological: Injection of C3BS-CQR-1
Biological: Sham, no injection
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
||Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.
Primary Outcome Measures:
- Efficacy between groups post-index procedure [ Time Frame: 39 weeks post-index ] [ Designated as safety issue: No ]
Change between groups from baseline and 39 weeks in a hierarchical composite outcome comprising, from most to least severe outcome, days to death from any cause, number of worsening of heart failure events, change in score for the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (10-point deterioration, no meaningful change,10-point improvement), change in six-minute walk distance (40-m deterioration, no meaningful change, 40-m improvement) and change in left ventricular end systolic volume (15-mL deterioration, no meaningful change, 15-mL improvement), and left ventricular ejection fraction (4% absolute deterioration, no meaningful change, 4% absolute improvement).
Secondary Outcome Measures:
- Efficacy and safety between groups post-index procedure [ Time Frame: 52 and 104 weeks post-index ] [ Designated as safety issue: Yes ]
Safety: Number and cause of deaths and re-admissions, number of cardiac transplantations, number of myocardial infarctions, number of strokes. Incidence of serious adverse events (AE) through week 104 and non-serious AEs (through week 52).
Efficacy: Time to all cause mortality, time to worsening of heart failure, and time to aborted sudden death through week 52.
Other Outcome Measures:
- Efficacy and safety between groups post-index procedure [ Time Frame: 39 and 52 weeks post-index ] [ Designated as safety issue: Yes ]
Time to all cause mortality, time to cardiovascular mortality, and rate of worsening heart failure requiring outpatient IV therapy for heart failure or readmission for heart failure, and others.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2014 (Final data collection date for primary outcome measure)
Sham Comparator: Control
Sham, no injection
Biological: Sham, no injection
Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
Experimental: C3BS-CQR-1 Treated
Injection of C3BS-CQR-1
Biological: Injection of C3BS-CQR-1
Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
|Ages Eligible for Study:
||18 Years to 80 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Eligible patients must meet all of the following inclusion criteria:
- Age ≥ 18 and < 80 years.
- Systolic dysfunction with left ventricular ejection fraction (LVEF) ≤ 30% as assessed by echocardiography.
- Ischemic heart failure without known need for revascularization.
- MLHFQ score > 30.
- Ability to perform a 6 minute walk test > 100 m and ≤ 400 m.
- History of hospitalization for heart failure (HF) within 12 months prior to screening.
- New York Heart Association (NYHA) Class III or IV despite optimal standard of care or Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) class 4, 5, 6 or 7.
- Use of ACE inhibitor and/or angiotensin receptor blocker (ARB); and beta blocker, for at least 3 months prior to screening visit, unless intolerant or contraindicated.
- Stable dosing of ACE inhibitor, angiotensin receptor blocker , beta blocker, aldosterone blocker,and diuretics for at least one month prior to screening visit, defined as ≤50% change in total dose of each agent.
- Willing and able to give written informed consent.
Exclusion Criteria (summarized):
Eligible patients must meet none of the following exclusion criteria:
- Women who are pregnant, confirmed by a positive urine or serum human chorionic gonadotropin laboratory test at screening.
- Women of child-bearing potential without a negative serum or urine pregnancy test at screening.
- Men refusing to exercise a reliable form of contraception.
- Myocardial infarction, unstable angina or percutaneous coronary intervention (PCI) within 90 days prior to screening, or coronary artery bypass graft surgery within 180 days prior to screening.
- Patient on a cardiac transplant list or previously received any solid organ transplant.
- Previously underwent cardiac surgery with remodeling procedure, left ventricular assist device placement or cardiomyoplasty.
- Patient has undergone cardiac resynchronization therapy within 6 months prior to screening.
- Severe uncontrolled HF requiring need for intensive intravenous diuretics or inotropic support within 1 month prior to screening.
Inability to perform a 6 minute walk test due to physical limitations other than HF including:
- Severe peripheral vascular disease
- Severe pulmonary disease or chronic obstructive pulmonary disease limiting exercise
- Orthopedic limitations, severe muscular diseases, any other joint or muscular disease or neurological disorder (such as an old stroke or neuropathy) limiting the ability to walk for 6 minutes.
- Dependence on chronic oral steroid therapy.
- Stroke or transient ischemic attack leading to limitations in lower extremities or occurring within 180 days prior to screening.
- Active myocarditis, constrictive pericarditis, restrictive, hypertrophic or congenital cardiomyopathy.
- BMI < 19 or > 45.
- Left ventricular thrombus.
- Left ventricular (LV) wall thickness < 8mm visualized in more than eight LV segments (50% of LV), and defined as a "LV no-go zone".
- LV aneurysm or candidate for surgical aneurysmectomy.
- Sustained ventricular tachycardia or ventricular fibrillation which led to automatic implantable cardioverter/defibrillator (AICD) therapy (shock) within 3 months prior to screening.
- Primary significant organic valvular heart disease.
- Moderate to severe aortic valve disease precluding catheter entry into the LV.
- Mechanical prosthetic valve in aortic or mitral position.
- Chronic infection or active malignancy.
- Patient has compromised renal function as reflected by a serum creatinine level >3.0 mg/dL or is currently on dialysis.
- Hematocrit < 28%.
- Atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree that could impede or preclude the safe retrograde passage of the delivery catheter.
- Chronic immunosuppressive therapy due to inflammatory or systemic disease.
- Patient tested positive for HIV 1 or 2, Hepatitis B or C, human T-cell lymphotrophic virus (HTLV) 1 or 2 (if required by regulations) or syphilis.
- Exposure to any previous experimental cell or angiogenic therapy and/or myocardial laser therapy and/or therapy with another investigational drug within 60 days prior to screening or enrollment in any concurrent study that may confound the results of this study.
- Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or in the opinion of the investigator are not suitable to participate.
- Any illness other than congestive heart failure which might reduce life expectancy to less than 2 years from screening.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01768702
|OLV Ziekenhuis Aalst
|Aalst, Belgium, 9300 |
|Contact: Marc Vanderheyden, MD +32 53 724435 Marc.Vanderheyden@olvz-aalst.be |
|Principal Investigator: Marc Vanderheyden, MD |
|Hopital Civil de Charleroi
|Charleroi, Belgium, 6000 |
|Contact: Dariouch Dolatabadi, MD +32 71 920668 email@example.com |
|Principal Investigator: Dariouch Dolatabadi, MD |
|Ziekenhuis Oost Limburg
|Genk, Belgium, 3600 |
|Contact: Joseph Dens, MD +32 89 327160 firstname.lastname@example.org |
|Principal Investigator: Joseph Dens, MD |
|UZ Leuven - Gasthuisberg
|Leuven, Belgium, 3000 |
|Contact: Stefan Janssens, MD +32 16 3442 35 email@example.com |
|Principal Investigator: Stefan Janssens, MD |
|Centre Hospitalier Universitaire de Liège
|Liège, Belgium, 4000 |
|Contact: Victor Legrand, MD +32 4 3667854 firstname.lastname@example.org |
|Principal Investigator: Victor Legrand, MD |
|Yvoir, Belgium, 5530 |
|Contact: Antoine Guedes, MD +32 81 4236 28 Antoine.Guedes@uclouvain.be |
|Principal Investigator: Antoine Guedes, MD |
||André Terzic, MD
||Mayo Clinic, Division of Cardiovascular Diseases, Rochester (MN, USA)
||Jozef Bartunek, MD
||OLV Ziekenhuis Aalst (Belgium)
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 21, 2012
||March 21, 2013
||Belgium: Federal Agency for Medicinal Products and Health Products
Keywords provided by Cardio3 BioSciences:
Chronic Heart Failure of Ischemic Origin
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 17, 2013